Company
Business
Stem Cell Therapy
Organoid
CDMO Business
Organoids are biologically relevant, three-dimensional models that recapitulate the structure and function of human organs, derived from human stem cells.
By faithfully reproducing cell–cell interactions and tissue-specific microenvironments, organoids overcome the inherent limitations of conventional two-dimensional cell cultures and animal models, positioning them as a next-generation research platform.
The global organoid market is predominantly driven by drug discovery and high-throughput screening, which accounts for approximately 40% of total applications. This is followed by disease modeling (25%) and toxicity testing (15%). In addition, regenerative medicine (10%) and other emerging applications continue to expand, highlighting a clear transition of organoid technology from a research-focused tool toward broader clinical and therapeutic applications.
Since 2021, the global organoid market has experienced double-digit compound annual growth, reflecting rapid expansion across biomedical research and pharmaceutical development. Looking ahead, the market is expected to enter an accelerated growth phase beyond 2025, driven by increasing demand for drug development, precision medicine, and human-relevant alternative testing platforms.
Kangstem biotech has accumulated over a decade of experience in organoid research and development, establishing a broad portfolio of organoid technologies including skin and islet organoids.
In particular, the company has developed advanced Assembloid technologies. Kangstem Biotech recreates the complex interactions between vascular and immune systems, enabling more precise modeling of human tissue structure and functions.
Based on these physiological characteristic, this platform addresses the limitations of conventional cell models and animal experiments, providing a more accurate system for predicting human biological responses.
Furthermore, by integrating organoids and Assembloids into standardized chip-based systems, developing next-generation organoid-on-a-chip platforms that closely mimic the human microenvironments.
Through these technologies, Kangstem Biotech is growing into a leading platform company that enhances the predictability of human responses in drug discovery, regenerative medicine, and advances alternative testing systems